Quest Laboratories Partners with Niraga Capitals for Strategic Advisory and Global Expansion

Key numbers

Market Cap	₹140.52 CrSME Segment
Revenue TTM	₹111.82 CrPharmaceuticals
P/E Ratio	9.36Sector P/E 49.7
Promoter Holding	66.78%Zero Pledge

Key highlights

• Strategic advisory collaboration initiated with Niraga Capitals Private Limited
• Focus on identification of overseas markets, distributors, and institutional buyers
• Evaluation of commercial alliances and licensing opportunities with global pharmaceutical firms
• Support for institutional business through government tenders and semi-government procurement
• Strategic capital evaluation including potential private equity or structured debt financing

What Is the Partnership?

Quest Laboratories has engaged Niraga Capitals Private Limited to provide a structured framework for advancing business, market, and corporate development opportunities. This collaboration follows an initial disclosure made on July 30, 2026, and is designed to support the company’s institutionalisation and strategic expansion. The advisory role covers capital planning and execution readiness while Quest maintains full responsibility for its operations and statutory matters.

The engagement aims to connect market opportunities with manufacturing capabilities and product strategy to drive long-term value through a coordinated work programme.

International and Institutional Growth

• Identifying suitable overseas distributors and strategic counterparties for contract manufacturing and private-label exports
• Evaluating commercial alliances with global healthcare organisations for licensing and technology partnerships
• Expanding institutional presence through hospital supply chains and government-based procurement tenders
• Assessing market-specific portfolio requirements to align manufacturing capacity with identified global and domestic demand
• Strengthening participation in bulk supply and other organised pharmaceutical distribution channels

Strategic Capital and Governance

A core component of the collaboration involves evaluating optimal capital structures to meet business requirements, including working capital and manufacturing augmentation. Niraga Capitals will assist Quest in exploring financing alternatives such as private equity, structured capital, and debt, subject to market conditions. Furthermore, the engagement seeks to enhance governance through improved management reporting, financial discipline, and investor communication.

These measures are intended to prepare the company for inorganic growth opportunities, including potential mergers, acquisitions, and joint ventures that complement existing operations.

Financial Context and Sector Dynamics

Quest Laboratories operates in the pharmaceutical sector with a trailing twelve-month revenue of 111.82 crore and a net profit of 15.02 crore. The company maintains a price-to-earnings ratio of 9.36, which sits below the broader sector average of 49.7. While the company saw a recent weekly price increase of 15.49 percent, its annual revenue growth stands at 5.69 percent.

This strategic shift towards advisory-led growth comes at a time when the sector faces 15.52 percent average quarterly revenue growth, highlighting the company's objective to enhance its institutional visibility and competitive positioning through external expertise.

Quest Laboratories · financial snapshot

Share price	₹85.75
Market capitalisation	₹140.52
Revenue (annual)	₹111.82
Net profit (annual)	₹15.02
P/E (TTM)	9.36×Sector 49.7×
Promoter holding	66.78%0.00% QoQ
FII holding	0.61%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.